Fig. 5: Quality of Life longitudinal assessments. | Nature Communications

Fig. 5: Quality of Life longitudinal assessments.

From: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Fig. 5

Mean change from baseline (±Standard Error) in EORTC QLQ-C30 for A Global Quality of Life and in EORTC QLQ-LC13 for B cough, C chest pain, D dyspnea (multi-scale item), and E composite symptom endpoint. Baseline was defined as the last assessment performed prior to administration of the first cycle of the study combination. The composite score was calculated as the mean of the scores for cough, dyspnea, and chest pain. Score changes of ≥10 points were considered clinically meaningful.

Back to article page